NAMS

NewAmsterdam Pharma Co N.V.

Pharmaceutical Preparations · SIC 2834CIK 1936258Held by 9 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$23.0M

Net Income FY2025

$(204.0M)

EPS (Basic, as reported)

$-1.72

Net Margin FY2025

-905.7%

ROE FY2025

-29.8%

Total Equity

$683.0M

Shares Out

120M

Business description

NewAmsterdam Pharma Co N.V. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2021–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 103 → 23 -39.3% CAGR

Fiscal yearFY2021⚑FY2022⚑FY2023FY2024FY2025

Revenue—103144623

Research & development(29)(87)(159)(151)(142)

Selling, general & administrative(6)(20)(38)(70)(106)

General & administrative—(14)(16)(14)(15)

Total operating expenses(35)(106)(197)(222)(248)

Operating income(35)(4)(183)(176)(226)

Interest expense00———

Interest & investment income——111728

Pre-tax income(42)(23)(177)(242)(204)

Income tax expense——00—

Net income(42)(23)(177)(242)(204)

EPS — basic($3.81)($1.19)($2.15)($2.56)($1.72)

EPS — diluted($3.81)($1.19)($2.15)($2.56)($1.72)

Shares outstanding — basic (M)11198294118

Shares outstanding — diluted (M)11198294118

⚑ Weighted-average shares changed ×1.73 between FY2021 and FY2022 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×4.32 between FY2022 and FY2023 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.